drugset
drugset / Trial / NCT02631642

A Study of HMPL-689 in Healthy Volunteers

NCT02631642 ↗

Phase 1 Completed 48 enrolled Hutchison Medipharma Limited
RandomizedParallel-groupQuadruple-blindHealth-services research

Summary

The purpose of this study is to evaluate the safety and tolerability of a single dose of HMPL-689 in healthy volunteers To determine the pharmacokinetic profile of single oral doses of HMPL-689 in healthy volunteers

Timeline

Start
2016-03-23
Primary completion
2016-10-26
Completion
2017-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject AMDIZALISIB Small molecule 1 mg Oral
Subject AMDIZALISIB Small molecule 2.5 mg Oral
Subject AMDIZALISIB Small molecule 5 mg Oral
Subject AMDIZALISIB Small molecule 10 mg Oral
Subject AMDIZALISIB Small molecule 20 mg Oral
Subject AMDIZALISIB Small molecule 25 mg Oral
Subject AMDIZALISIB Small molecule 30 mg Oral

Indications

No indication recorded.